Supplementary Figure 1 : Laboratory and analysis workflow. a) Total DNA is extracted from patient blood and libraries are prepared, probes targeting exons of interest are used for bait capture. The enriched libraries are sequenced and the results are analyzed against a reference sequence to detect variants. In parallel, total RNA is extracted from patient blood and cDNA libraries are prepared. Exon targeting probes are used for bait capture to allow detection of novel exons and the enriched libraries are sequenced and results processed with a custom analysis pipeline. b) Healthy controls and patient samples are analyzed identically. Once samples have passed pipeline QC (85% of exons with coverage >50x), splicing analysis is performed, and coverage and PSI cutoffs are applied (PSI>5% with splicing event coverage>50x). Only PSI values that are significantly higher than the mean control PSI are reported. Alternative splicing events are then associated with a given DNA splicing variant, here an exon skipping event associated with the abolishment of the native acceptor site is shown. c) Splicing events reported in this analysis include full exon skipping, partial exon skipping (alternative 5' donor or 3' acceptor), full and partial exon skipping, partial intron retention (exon extension), and intron inclusion (cryptic exon) relative to the canonical transcript with no alternative splicing. Constitutive (no alternative splicing) 
